(Q36102406)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Christopher Griffiths

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Naldi L

series ordinal

1

1 reference

12 August 2017

Griffiths CE

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Dermatology

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

597-615

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15840088%20AND%20SRC:MED&resulttype=core&format=json

Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Quality of life of psoriasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Quality of life issues in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Physical and psychologic measures are necessary to assess overall psoriasis severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

A systematic review of five systemic treatments for severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Phototherapy treatment of psoriasis today

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

AAD consensus statement on psoriasis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Phototherapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Toxic effects of ultraviolet radiation on the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Taking treatment to the patient: development of a home TL-01 ultraviolet B phototherapy service

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Combination therapy to treat moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Photo(chemo)therapy: general principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Non-Melanoma Skin Cancer Occurring in Patients Treated With PUVA Five to Ten Years After First Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

The risk of melanoma in association with long-term exposure to PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Ciclosporin in psoriasis clinical practice: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Cyclosporine immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Treatment of psoriasis. Part 2. Systemic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Fumaric acid esters, their place in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

The immunologic basis for the treatment of psoriasis with new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

Long-term safety of cyclosporine in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X

An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06563.X